Background: Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1 expression may help in breast cancer prognosis.
Methods: We will conduct a systematic review of observational or interventional studies evaluating the prognostic ability of PD-L1 expression levels in predicting positive clinical outcomes in Human Breast Cancer. A sensitive search strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data. The outcomes evaluated will be Overall Survival, Breast Cancer-specific Survival, Disease-free Survival, Recurrence-free Survival, Positive Lymph Node, and Distant Metastasis. The outcomes will be extracted directly from the studies, if available. Methodological quality and bias of included studies will be assessed using a standardized checklist and overall quality of evidence will be assessed through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. If meta-analysis is possible, the measures of association will be calculated using bivariate random-effects models. Statistical heterogeneity will be evaluated with I statistics and explored through sensitivity analysis.
Discussion: Immunomodulation seems to be a promising strategy in solid tumors. Breast cancer is the most common malignancies in women worldwide, and one of the leading causes of cancer death. PD-1 and PD-L1 are key physiologic suppressors of the cytotoxic immune reaction.
Trial Registration: Systematic review registration: CRD42019121118 (PROSPERO).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098137 | PMC |
| http://dx.doi.org/10.1186/s13643-020-01306-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Body Image Disturbance and Its Influencing Factors in Breast Cancer Patients Following Unilateral Mastectomy.
Psychiatry Clin Psychopharmacol
December 2024
Department of Operating Room, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, China.
Background: Patients with unilateral breast loss after single mastectomy for breast cancer may have body image disorders such as surgical lymphedema, flap ischemia, and spinal deformity, resulting in negative emotions such as depression, inferiority, and social dysfunction. This study mainly investigated and analyzed the status quo and influencing factors of body image disorder in breast cancer patients after single mastectomy.
Methods: This study is a cross-sectional study.
Optimized Synthetic Correlated Diffusion Imaging for Improving Breast Cancer Tumor Delineation.
Sensors (Basel)
December 2024
Department of Systems Design Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Breast cancer is a significant cause of death from cancer in women globally, highlighting the need for improved diagnostic imaging to enhance patient outcomes. Accurate tumor identification is essential for diagnosis, treatment, and monitoring, emphasizing the importance of advanced imaging technologies that provide detailed views of tumor characteristics and disease. Recently, a new imaging modality named synthetic correlated diffusion imaging (CDI) has been showing promise for enhanced prostate cancer delineation when compared to existing MRI imaging modalities.
View Article and Find Full Text PDFMR Elastography Using the Gravitational Transducer.
Sensors (Basel)
December 2024
Research Department of Imaging Physics and Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London WC2R 2LS, UK.
MR elastography is a non-invasive imaging technique that provides quantitative maps of tissue biomechanical properties, i.e., elasticity and viscosity.
View Article and Find Full Text PDFA New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.
Pharmaceutics
December 2024
Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlândia, Patos de Minas 38700-002, MG, Brazil.
: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (-) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells.
View Article and Find Full Text PDFOrganic Moiety on Sn(IV) Does Matter for In Vitro Mode of Action: BuSn(IV) Compounds with Carboxylato -Functionalized 2-Quinolones Induce Anoikis-like Cell Death in A375 Cells.
Pharmaceutics
November 2024
Department of Chemistry and Biochemistry, Faculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Belgrade, Serbia.
New tributyltin(IV) complexes containing the carboxylate ligands 3-(4-methyl-2-oxoquinolin-1(2H)-yl)propanoic acid () and 2-(4-methyl-2-oxoquinolin-1(2H)-yl)acetic acid () have been synthesized. Their structures have been determined by elemental microanalysis, FT-IR and multinuclear NMR (H, C and Sn) spectroscopy and X-ray diffraction study. A solution state NMR analysis reveals a four-coordinated tributyltin(IV) complex in non-polar solvents, while an X-Ray crystallographic analysis confirms a five-coordinated trigonal-bipyramidal geometry around the tin atom due to the formation of 1D chains.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!